BEX1 acts as a tumor suppressor in acute myeloid leukemia

Acute myeloid leukemia (AML) is a heterogeneous disease of the myeloid lineage. About 35% of AML patients carry an oncogenic FLT3 mutant making FLT3 an attractive target for treatment of AML. Major problems in the development of FLT3 inhibitors include lack of specificity, poor response and developm...

Descripción completa

Detalles Bibliográficos
Autores principales: Lindblad, Oscar, Li, Tianfeng, Su, Xianwei, Sun, Jianmin, Kabir, Nuzhat N., Levander, Fredrik, Zhao, Hui, Lu, Gang, Rönnstrand, Lars, Kazi, Julhash U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673273/
https://www.ncbi.nlm.nih.gov/pubmed/26046670

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673273/
https://www.ncbi.nlm.nih.gov/pubmed/26046670

Ejemplares similares